Pfizer and Bristol Myers are racing to strengthen oncology portfolios through deals, new drugs and pipelines ??? investors ...

Shantanu Narayen led Adobe through a transition to subscription software, and he's been positioning the company to grow in ...

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with ...

These dividend stocks are built for the long haul.

Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on PFE.

Pfizer Inc. (NYSE:PFE) is one of Goldman Sachs top healthcare stocks. On March 9, analysts at BMO reiterated an Outperform rating on Pfizer Inc. (NYSE:PFE) and a $30 price target.

Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.

Shares of Pfizer Inc. PFE slid 1.04% to $26.58 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.61% to 6,632.19 and Dow Jones ...

Pfizer’s CEO, Albert Bourla, Ph.D., has yet to top the $33 million in compensation that he earned on the coattails of megablockbuster COVID-19 sales in 2022, but a $27.6 million pay package after a ...

The stock now trades at a dividend yield of 6.5%. Despite continued pricing pressure, Pfizer stock looks cheap for investors today. Investors may have thought they were out of the woods as Pfizer ...

Pfizer (PFE) ended the recent trading session at $26.86, demonstrating a -1.61% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 1.52% for ...

This darling of the Covid era has given back considerable gains in recent years, but it could be on the verge of a turnaround ...